You are viewing the site in preview mode
Skip to main content
|
Body composition measurement
| |
ER+ tumors
| | |
ER– tumors
| |
|---|
|
p-mTOR overexpressed cases vs controls
|
p-mTOR negative/low cases vs controls
|
P-heterogeneity
|
p-mTOR overexpressed cases vs controls
|
p-mTOR negative/low cases vs controls
|
P-heterogeneity
|
|---|
|
OR (95% CI)
|
OR (95% CI)
| |
OR (95% CI)
|
OR (95% CI)
| |
|---|
|
Percent body fat
|
|
No. of cases/no. of controls
|
156/1884
|
295/1884
| |
23/1884
|
198/1884
| |
|
Q1
|
1.00 [reference]
|
1.00 [reference]
| |
1.00 [reference]
|
1.00 [reference]
| |
|
Q2
|
1.29 (0.73–2.28)
|
1.10 (0.76–1.60)
| |
1.08 (0.28–4.20)
|
1.53 (0.99–2.36)
| |
|
Q3
|
1.61 (0.93–2.78)
|
1.06 (0.71–1.50)
| |
1.20 (0.31–4.58)
|
0.84 (0.52–1.36)
| |
|
Q4
|
1.31 (0.74–2.32)
|
0.67 (0.44–1.01)
|
0.037
|
1.34 (0.36–4.95)
|
0.73 (0.45–1.19)
|
0.003
|
|
P-trend
|
0.31
|
0.06
| |
0.64
|
0.040
| |
|
Fat mass index
|
|
No. of cases/no. of controls
|
155/1859
|
294/1859
| |
23/1859
|
198/1859
| |
|
Q1
|
1.00 [reference]
|
1.00 [Reference]
| |
1.00 [Reference]
|
1.00 [reference]
| |
|
Q2
|
1.26 (0.71–2.23)
|
1.24 (0.85–1.80)
| |
1.06 (0.27–4.41)
|
1.59 (1.02–2.47)
| |
|
Q3
|
1.36 (0.77–2.38)
|
1.19 (0.81–1.74)
| |
1.23 (0.33–4.61)
|
0.89 (0.55–1.45)
| |
|
Q4
|
1.48 (0.84–2.60)
|
0.72 (0.47–1.10)
|
0.011
|
1.09 (0.29–4.20)
|
0.79 (0.48–1.30)
|
0.004
|
|
P-trend
|
0.19
|
0.040
| |
0.90
|
0.031
| |
- Abbreviations: ER estrogen receptor, OR odds ratio, Q quartile
- Models adjusted for age, race, family history of breast cancer, menopausal status, age of menarche, parity, history of breastfeeding, oral contraceptive use, history of diabetes
